(S (S (VP (VBG Building) (PP (PP (IN on) (NP (NP (NNP Yu) (CC and) (NNP Kumbier) (POS 's)) (NNP PCS) (NN framework))) (CC and) (PP (IN for) (NP (JJ randomized) (NNS experiments)))))) (, ,) (NP (PRP we)) (VP (VBP introduce) (NP (NP (DT a) (JJ novel) (NN methodology)) (PP (IN for) (NP (NP (JJ Stable) (NNP Discovery)) (PP (IN of) (NP (NNP Interpretable) (NNP Subgroups))) (PP (IN via) (NP (NNP Calibration))))) (PRN (-LRB- -LRB-) (NP (NNP StaDISC)) (-RRB- -RRB-)) (, ,) (PP (IN with) (NP (JJ large) (JJ heterogeneous) (NN treatment) (NNS effects))))) (. .))
(S (NP (NNP StaDISC)) (VP (VBD was) (VP (VBN developed) (PP (IN during) (NP (NP (PRP$ our) (NN re-analysis)) (PP (IN of) (NP (NP (DT the) (CD 1999-2000) (NNP VIGOR) (NN study)) (, ,) (NP (DT an) (ADJP (CD 8076) (NN patient)) (VBD randomized) (JJ controlled) (NN trial)) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBN compared) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ adverse) (NNS events))) (PP (IN from) (NP (NP (DT a) (ADJP (RB then) (RB newly) (VBN approved)) (NN drug)) (, ,) (NP (NP (NNP Rofecoxib)) (PRN (-LRB- -LRB-) (NP (NNP Vioxx)) (-RRB- -RRB-))) (, ,)))) (PP (TO to) (NP (NP (IN that)) (PP (IN from) (NP (NP (DT an) (JJR older) (NN drug)) (NP (NNP Naproxen))))))))))))))) (. .))
(S (NP (NNP Vioxx)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (PRN (, ,) (PP (PP (IN on) (NP (NN average))) (CC and) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NNP Naproxen)))))) (, ,)) (VP (VP (VB reduce) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ gastrointestinal) (PRN (-LRB- -LRB-) (NNP GI) (-RRB- -RRB-)) (NNS events))))) (CC but) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ thrombotic) (NN cardiovascular) (PRN (-LRB- -LRB-) (NNP TC) (-RRB- -RRB-)) (NNS events)))))))))) (. .))
(S (S (VP (VBG Applying) (NP (NNP StaDISC)))) (, ,) (NP (PRP we)) (VP (VP (VBP fit) (NP (CD 18) (JJ popular) (JJ conditional) (NN average) (NN treatment) (NN effect) (PRN (-LRB- -LRB-) (NNP CATE) (-RRB- -RRB-)) (NNS estimators)) (PP (IN for) (NP (DT both) (NNS outcomes)))) (CC and) (VP (VB use) (NP (NN calibration)) (S (VP (TO to) (VP (VB demonstrate) (NP (PRP$ their) (JJ poor) (JJ global) (NN performance))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (PRP they)) (VP (VBP are) (ADJP (RB locally) (JJ well-calibrated) (CC and) (JJ stable)) (, ,) (S (VP (VBG enabling) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (NP (JJ patient) (NNS groups)) (PP (IN with) (NP (JJR larger) (PP (IN than) (PRN (-LRB- -LRB-) (VBN estimated) (-RRB- -RRB-)) (JJ average) (NN treatment) (NNS effects)))))))))) (. .))
(S (PP (IN In) (NP (NN fact))) (, ,) (NP (NNP StaDISC)) (VP (VBZ discovers) (NP (NP (NP (CD three) (ADJP (RB clinically) (JJ interpretable)) (NNS subgroups)) (PP (IN for) (NP (DT the) (NNP GI) (NN outcome))) (PRN (-LRB- -LRB-) (VP (VBG totaling) (NP (NP (CD 29.4) (NN %)) (PP (IN of) (NP (DT the) (NN study) (NN size))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (CD two)) (PRN (-LRB- -LRB-) (VP (VBG totaling) (NP (CD 5.6) (NN %))) (-RRB- -RRB-)) (PP (IN for) (NP (DT the) (NNP TC) (NN outcome)))))) (. .))
(S (PP (NNP Amongst) (NP (PRP them))) (, ,) (NP (NP (DT the) (NN subgroup)) (PP (IN of) (NP (NP (NNS people)) (PP (IN with) (NP (NP (DT a) (JJ prior) (NN history)) (PP (IN of) (NP (NNP GI) (NNS events))))))) (PRN (-LRB- -LRB-) (NP (NP (CD 7.8) (NN %)) (PP (IN of) (NP (DT the) (NN study) (NN size)))) (-RRB- -RRB-))) (VP (CONJP (RB not) (RB only)) (VP (VBZ has) (NP (NP (DT a) (ADJP (RB disproportionately) (VBN reduced)) (NN risk)) (PP (IN of) (NP (NNP GI) (NNS events))))) (CONJP (CC but) (RB also)) (VP (VBZ does) (RB not) (VP (VB experience) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP TC) (NNS events))))))) (. .))
